China 2020: The Biotech Boom, Market Opportunities and the Impact of the Coronavirus

May 7, 2020 8:00 AM - 9:30 AM

Webinar, click "live-stream" button to view

Add to Calendar 5/7/2020 8:00:00 AM 5/7/2020 9:30:00 AM China 2020: The Biotech Boom, Market Opportunities and the Impact of the Coronavirus

There is a biotech boom happening in China. Once focused mostly on generic drugs, a dramatic shift towards innovation is underway today. A perfect storm of positive changes is catalyzing the ideal environment for this to take place:

- totally revamped China FDA – the National Medical Products Administration (NMPA) – has harmonized with global regulatory standards;
- new Hong Kong and Shanghai STAR Board stock exchange rules that provide listing venues for companies for the first time;
- government reimbursement (NRDL) of innovative medicines that is now happening with regular frequency;
- a clinical trial network with high quality standards is coming online. This may speed up and lower the cost of drug development in the future;
- world class science and leading-edge drug discovery that is reflective of the country’s large talent pool;
- huge growth of CROs and CMOs;
- an aging society that is looking for the best new medicines.
 

These developments are turning China biotech into a pillar of growth for the industry that can benefit both domestic and foreign companies alike. In December 2019, a new and startling factor came into play. The country began to battle an outbreak of a novel coronavirus known as SARS-CoV-2. China, WHO, nations globally and the collective biotech industry responded immediately to stem the spread of the disease and create therapies against it. It’s a lot of information to digest and understand regarding the market opportunity and impacts on our industry given all the recent news. Our forum is designed to bring you up to speed.

A panel of experts with on the ground and business experience in China will familiarize the audience with the current state of the biopharma industry there and novel approaches they are seeing to the market as well as the impact of the coronavirus. They’ll discuss what this means for the MassBio community and the US biopharma industry, what US companies from early stage to large pharma are doing to take advantage of the market and its investors, to collaborate with Chinese based entities and to maximize their chance of succeeding in this large and sometimes complicated market.

Sponsored by the MassBio Business Development and Finance forum working group.

MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.

 Webinar, click "live-stream" button to view
Vice President, Head of DMPK and Preformulation at KSQ Therapeutics
Hanlan Liu has more than 20 years of drug R&D experience at Ostuka, Wyeth-Ayerst Research, Genzyme, Sanofi, and Catabasis Pharmaceuticals. Currently, she serves as Vice President, Head of DMPK and Preformulation at KSQ Therapeutics. Prior to joining KSQ Therapeutics, Hanlan served as Executive Director and Head of DMPK and Clinical Pharmacology at Catabasis Pharmaceuticals where she led non-clinical strategy and work plan development for edasalonexent, an NF-B inhibitor currently in Phase 3 clinical trial for Duchenne Muscular Dystrophy. Before Catabasis, Hanlan spent 14 years at Genzyme and then Sanofi with increasing responsibilities and ultimately promoted to Senior Director in DMPK. During her tenure at Genzyme and Sanofi, Hanlan built and led multiple collaborative and science-driven pharmaceutics function groups associated with more than 30 drug discovery projects in multiple disease areas, several of which advanced to clinical trials. She contributed to 5 INDs and several product submissions and/or post market drug life cycle dossiers including those for Hectorol®, Mozobil®, Mipomerson® and Cerdelga®. Hanlan began her career in Ostuka in analytical and formulation and then Wyeth-Ayerst Research in early drug discovery. Hanlan earned her PhD of Analytical Medicinal Chemistry and Molecular Pharmacology and conducted postdoctoral work at Purdue University prior to completing her MBA at New York University. Hanlan graduated with a BS in Biochemistry at Wuhan University. Hanlan is the co-inventor on 6 patents and co-author of 33 scientific publications.